Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 16/20 | 0.43 |
| ▸ | PPARA | Q07869 | 9/20 | 0.43 |
| ▸ | PPARD | Q03181 | 8/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6028635 | 0.91 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL4432117 | 0.79 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL6017213 | 0.76 | PPARD (0.47) | PPARGPPARAPPARDGRIN1GRIN2B | |
| SCHEMBL6017182 | 0.76 | PKM (0.40) | PPARGPPARAPPARD | |
| SCHEMBL6030489 | 0.75 | PPARD (0.48) | PPARGPPARAPPARDGRIN1GRIN2B | |
| SCHEMBL6029170 | 0.75 | MCL1 (0.41) | PPARGPPARAPPARDGRIN1GRIN2B | |
| SCHEMBL5017192 | 0.75 | PPARD (0.45) | PPARGPPARAPPARD | |
| SCHEMBL4424891 | 0.74 | PPARG (0.50) | PPARGPPARAPPARD | |
| SCHEMBL5015488 | 0.74 | PPARG (0.51) | PPARGPPARAPPARD | |
| SCHEMBL6029484 | 0.73 | PPARD (0.50) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682535-A1 | HETEROARYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| US-6995263-B2 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-02-07 | — | — | US | disclosed |
| WO-2005049606-A1 | HETEROARYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.